SSY Group Crecimiento futuro

Future controles de criterios 5/6

Se prevé un crecimiento anual de los beneficios y los ingresos de SSY Group de 20.9% y 21% respectivamente, mientras que el BPA crecerá en un 21.1% al año.

Información clave

20.9%

Tasa de crecimiento de los beneficios

21.1%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	23.5%
Tasa de crecimiento de los ingresos	21.0%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	24 Jul 2023

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Previsiones de crecimiento de beneficios e ingresos

OTCPK:LJUI.F - Estimaciones futuras de los analistas y datos financieros pasados (HKD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2025	12,473	2,161	N/A	1,801	2
12/31/2024	9,831	1,759	1,017	1,333	4
12/31/2023	7,945	1,431	578	945	4
12/31/2022	6,434	1,123	316	734	N/A
9/30/2022	6,376	1,101	318	752	N/A
6/30/2022	6,318	1,080	321	769	N/A
3/31/2022	5,838	933	314	733	N/A
12/31/2021	5,357	786	307	696	N/A
9/30/2021	5,139	713	205	605	N/A
6/30/2021	4,921	641	102	514	N/A
3/31/2021	4,591	626	143	509	N/A
12/31/2020	4,261	612	183	505	N/A
9/30/2020	4,177	723	140	558	N/A
6/30/2020	4,093	835	97	611	N/A
3/31/2020	4,364	985	-47	628	N/A
12/31/2019	4,636	1,136	-190	646	N/A
9/30/2019	4,525	1,075	-164	629	N/A
6/30/2019	4,414	1,014	-138	612	N/A
3/31/2019	4,297	963	126	791	N/A
12/31/2018	4,181	912	390	970	N/A
9/30/2018	4,012	867	385	906	N/A
6/30/2018	3,844	822	380	843	N/A
3/31/2018	3,460	743	279	698	N/A
12/31/2017	3,076	665	179	552	N/A
9/30/2017	2,827	616	283	676	N/A
6/30/2017	2,577	567	387	799	N/A
3/31/2017	2,469	528	375	743	N/A
12/31/2016	2,361	490	364	686	N/A
9/30/2016	2,315	426	N/A	579	N/A
6/30/2016	2,270	363	N/A	472	N/A
3/31/2016	2,246	383	N/A	517	N/A
12/31/2015	2,222	403	N/A	563	N/A
9/30/2015	2,189	443	N/A	326	N/A
6/30/2015	2,156	482	N/A	89	N/A
3/31/2015	2,124	487	N/A	198	N/A
12/31/2014	2,091	492	N/A	308	N/A
6/30/2014	1,309	402	N/A	613	N/A
3/31/2014	1,516	386	N/A	605	N/A
12/31/2013	1,723	369	N/A	598	N/A
9/30/2013	2,681	386	N/A	594	N/A
6/30/2013	2,618	359	N/A	590	N/A
3/31/2013	2,524	320	N/A	416	N/A
12/31/2012	2,431	281	N/A	242	N/A
9/30/2012	2,360	127	N/A	184	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (20.9% al año) de LJUI.F es superior a la tasa de ahorro (2.1%).

Beneficios vs. Mercado: Se prevé que los beneficios (20.9% al año) de LJUI.F crezcan más rápidamente que el mercado US (14.4% al año).

Beneficios de alto crecimiento: Se espera que los beneficios de LJUI.F crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (21% al año) de LJUI.F crezcan más rápidamente que los del mercado US (7.9% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (21% al año) de LJUI.F crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de LJUI.F se prevé que sea elevada dentro de 3 años.

SSY Group Crecimiento futuro

Future controles de criterios 5/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

SSY Group Limited Provides Update on Product Development

SSY Group Limited, Annual General Meeting, May 17, 2024

SSY Group Limited Announces Final Dividend for the Year Ended 31 December 2023, Payable on 04 June 2024

SSY Group Limited Announces Update on Product Development

SSY Group Limited to Report Fiscal Year 2023 Results on Mar 27, 2024

SSY Group Limited Obtains Approval for Drug Production and Registration for Nicorandil for Injection (12mg) from the National Medical Products Administration of China

SSY Group Limited Announces its Norepinephrine Bitartrate Obtains the Approval for Registration from the National Medical Products Administration of China to Become a Bulk Drug for the Preparations on the Market

SSY Group Limited Receives Approval for Gliclazide Tablet

SSY Group Limited Provides Update on Product Development

SSY Group Limited Obtains the Approval for Drug Production and Registration for Propofol Medium and Long Chain Fat Emulsion Injection from the National Medical Products Administration of China

SSY Group Limited Announces Update on Product Development

SSY Group Limited Provides Update on Product Development

SSY Group Limited Appoints Liu Wenjun as Non-Executive Director

Ssy Group Limited Provides Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Obtains Approval for Drug Production and Registration for Ropivacaine Hydrochloride and Sodium Chloride Injection from National Medical Products Administration of China

SSY Group Limited Provides Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces Update on Product Development

National Medical Products Administration of China Accepts Application for Phase I Clinical Trial of the SSY Group Limited 'S SYN-045

SSY Group Limited Announces Resignation of Feng Hao as Non-Executive Director, Effective from 1 November 2023

SSY Group Limited Obtains Approvals for Drug Production and Registration for Aminophylline Injection

SSY Group Limited Announces Update on Product Development

SSY Group Limited Obtains Approvals for Drug Production and Registration for Ondansetron Hydrochloride Tablets from the National Medical Products Administration of China

SSY Group Limited Provides Update on Product Development

SSY Group Limited Obtains the Clinical Trial Approval Issued By the National Medical Products Administration of China for Alprostadil Injection

SSY Group Limited Obtains the Approval for Drug Production and Registration for Linezolid and Sodium Chloride Injection (300ml) from the National Medical Products Administration of China

SSY Group Limited Obtains the Approvals for Drug Production and Registration for Tinidazole Tablets (0.5G) and Ornidazole Tablets (0.5G) from the National Medical Products Administration of China

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Provides Update on Product Development

Ssy Group Limited Announces Interim Dividend for the Six Months Ended 30 June 2023, Payable on 27 September 2023

SSY Group Limited Announces Update on Product Development

SSY Group Limited to Report First Half, 2023 Results on Aug 29, 2023

SSY Group Limited Obtains Approval for Drug Production and Registration for Stiripentol for Suspension (500Mg and 250Mg) from the National Medical Products Administration of China

SSY Group Limited Obtains Approval for Drug Production and Registration for Oseltamivir Phosphate for Suspension

SSY Group Limited Provides Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Obtains Approval for Drug Production and Registration for Citicoline Sodium Injection from the National Medical Products Administration of China

SSY Group Limited Obtains the Approvals for Drug Production and Registration for Urapidil Hydrochloride Injection

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces the Retirement of Mr. Leung Chong Shun as Independent Non-Executive Director, Chairman of the Remuneration Committee of the Company, A Member F the Audit Committee of the Company and A Member of the Nomination Committee

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces the Group's Tinidazole Obtains the Approval for Registration from the National Medical Products Administration of China

SSY Group Limited Updates on Product Development

SSY Group Limited Obtains the Approval for Registration from the National Medical Products Administration of China to Become A Bulk Drug for the Preparations on the Market

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento